Sidley Represents NextCure in Merger With Avere Therapeutics and Concurrent US$320 Million Private Placement

Sidley represented NextCure, Inc. (Nasdaq: NXTC) in its definitive merger agreement with Avere Therapeutics, Inc. in an all-stock transaction. Upon closing, which is expected to occur in the second half of 2026, the combined company is expected to operate as Avere Therapeutics, Inc. and trade on the Nasdaq Stock Market. The transaction includes a concurrent US$320 million private placement financing led by Fairmount and Hansoh Pharmaceutical Group Co., Ltd.

More information about the transaction is available here.

The Sidley team was led by Asher Rubin (Technology and Life Sciences Transactions), Nick DeAngelis (M&A), and Istvan Hajdu (Capital Markets), and included Alison Lehner (Emerging Companies and Venture Capital); Andrea Reed (Corporate Governance); Karim Pirani (Employee Benefits and Executive Compensation); Molly Homann and Kelly Katherine Ball (M&A); Amanda Chong Artese (Technology and Life Sciences Transactions); Henry Dickinson (Capital Markets); and Christian Brause and Daniel Venetucci (Tax).